Chronos Archive seal

Review checklist: Evel Knievel (HR-RB001)

All records · Back to the record · Dossier (sources.md) · Terminology · Report a problem · Comments

Everything a reviewer needs to judge, gathered from the record. Release status: draft.

Review status

ReviewStatusReviewerDateNotes
schema validationnot_startedRun scripts/build.ps1 -Conformance.
clinical reviewnot_startedAwaiting clinician review; check the diagnostic pathway, the staging (FIB-4, elastography, Child-Pugh, MELD-Na), the choice of sofosbuvir-velpatasvir with the drug interaction check, carvedilol without screening endoscopy under Baveno VII, HCC surveillance after cure, the pain plan without NSAIDs or opioids, continuous glucose monitoring in cirrhosis, and zoledronic acid rather than an oral bisphosphonate.
provenance reviewnot_startedRecent-death rule: only what he made public, what was reported during his life, and obituaries and record-keeper accounts: the Associated Press, ESPN, Reuters, the Deseret News and Guinness World Records. The stage of his liver disease and any treatment before the 1999 transplant were not made public; everything clinical is synthetic.
safe messaging reviewnot_startedThe drinking reported in a Reuters obituary (CLM-0006) and the drug pump for pain in his last year (CLM-0008) are marked sensitive. No diagnosis of an alcohol or opioid use disorder is made; alcohol appears only as counseling and AUDIT-C scores, which are synthetic. Mood screens are synthetic and below the threshold for a safety assessment. His 1977 conviction is not medical and is left out. No relative is named or given a role.

Judgment calls (dossier editorial resolutions)

  1. Recent-death rule. Knievel died in 2007, so the rule applies. The case uses only what was reported in obituaries and record-keeper accounts (the Associated Press, ESPN, Reuters, the Deseret News and Guinness World Records) and his own words in a newspaper interview quoted by Reuters. No sick visit is added. His death is recorded once (CLM-0009), in plain words. Two claims are marked sensitive: the Reuters report that he did not stop drinking until his 1999 transplant (CLM-0006) and the implanted drug pump for pain in his last year (CLM-0008).
  2. Alcohol. The roster lists “alcohol use disorder.” No source fetched gives that diagnosis, so none is made: there is no F10 code, and alcohol appears only in the social history, as AUDIT-C scores and as counseling, all synthetic and anchored to the obituary report. The modern episode has him cut down after counseling and stop when treatment starts; this is a synthetic course and implies nothing about his real drinking. No safety assessment is required (no behavioral-health code; PHQ-9 at most 6; PHQ-2 at most 1).
  3. What is not public. When his hepatitis C was diagnosed, the stage of his liver disease before the transplant, and any treatment he had were not made public; one secondary page dates the diagnosis to 1993, but it is not a reliable source and is not used. Every clinical detail in the modern episode (the presenting tests, genotype 1a, the viral load, liver stiffness, Child-Pugh and MELD-Na, carvedilol, sofosbuvir-velpatasvir and cure, osteoporosis, all values) is synthetic. The modern course ends in cure with compensated cirrhosis, as current treatment allows; it does not describe his real course, in which he needed a liver transplant three years after the true-frame index date.
  4. Fractures. CLM-0004 records the conflict: Guinness World Records lists 433 bone fractures by the end of 1975 under “most broken bones in a lifetime,” while the Associated Press obituary says nearly 40 broken bones before he retired in 1980. The claim is graded D with certainty “disputed,” and the modern episode says “dozens of fractures.” Other counts reported on Wikipedia, including his own lower estimate, are not cited.
  5. Conflicts and gaps. (1) The Caesars Palace crash is dated 1968 in the wire obituaries; the jump is usually dated to New Year’s Eve 1967, and later accounts dispute the month-long coma; CLM-0002 is graded probable and uses the obituaries’ year. (2) Cause of death: the roster says pulmonary fibrosis caused his death; the obituaries fetched report natural causes after years of diabetes and pulmonary fibrosis, so CLM-0009 states that. (3) The year of the pulmonary fibrosis diagnosis (2005 on Wikipedia, without a fetched source) and the dates of the two strokes are not stated; both conditions came after the index age and are not used in the modern episode. (4) The liver transplant hospital and month are not stated (secondary sources not used). (5) The New York Times obituary, Britannica and Smithsonian pages returned access errors and are not cited. (6) Hepatitis C is described as “likely contracted through a blood transfusion”; the modern episode treats transfusion before 1992 as the likely source, as the obituaries do.
  6. Left out. His 1977 assault conviction is not medical and is left out. The lawsuit, finances and family history reported in the obituaries are left out. No relative is named; the sons and granddaughter quoted in the obituaries have no role, and no health fact, statement or decision is attributed to any relative. The modern family history is left empty. The roster’s “PTSD from career injuries” has no source and is not used.
  7. Alias. “Robert Craig Knievel” is used as the alias; it appears in no other record. “Bob” and “Robert” alone are not used.
  8. Index age and dates. The index visit on January 12, 2026 maps to January 12, 1996, when he was 57, three years before the 1999 transplant. The synthetic date of birth is October 17, 1968 (shift 30 years). The chronic-care visits on January 26, February 23, May 18 and August 17, 2026 and the preventive visit on September 21, 2026 (age 57, so a periodic adult preventive visit) map to the same days of 1996, within his lifetime and before the transplant. The presenting-problem pattern is used: raised transaminases with low platelets (R74.01) are a resolved problem when hepatitis C with cirrhosis is diagnosed at the consultation. The claims about the transplant, drinking until the transplant, his last years and his death are linked to timeline events after the index date, so the intake documents do not show them.
  9. Diabetes and pain at the index age. His diabetes and chronic pain are documented only for his last years. Placing type 2 diabetes on metformin and chronic pain from old fractures at 57 is a synthetic choice that serves the teaching objective; both problems are linked to the documented claims and marked synthetic.
  10. Synthetic clinical picture and teaching points. Cirrhosis is diagnosed without biopsy (FIB-4 4.94, liver stiffness 26.8 kPa, nodular liver, splenomegaly, platelets 118). Sofosbuvir-velpatasvir was chosen over glecaprevir-pibrentasvir because the latter should not be given with atorvastatin; the proton pump inhibitor is stopped. Liver stiffness of 25 kPa or more establishes clinically significant portal hypertension under Baveno VII, so carvedilol is started and screening endoscopy is not done; this differs from the endoscopic surveillance named on the AASLD-IDSA page and follows the newer Baveno VII and AASLD 2024 portal hypertension guidance. Transplant evaluation is not indicated (compensated; MELD-Na 8, then 6). The A1c reads below the glucose management indicator, as it can in cirrhosis, so a continuous glucose monitor guides diabetes care. Osteoporosis is treated with zoledronic acid rather than an oral bisphosphonate because of portal hypertension. Pain care avoids oral NSAIDs and opioids. Qualitative results (serology, genotype, ultrasound, elastography details, DXA, retinal examination) appear in procedure and note text; liver stiffness and HCV RNA are coded. Height (178 cm) and weights are synthetic.
  11. Preventive visit. A periodic adult preventive visit at 57 (CPT 99396 with 99497 in plain text), five weeks after the test of cure. Judgment calls: colonoscopy ordered (never screened); PSA after shared decision-making; lung cancer screening not indicated (synthetic never-smoker); influenza, PCV20, recombinant zoster dose 1 and Tdap given; COVID-19 vaccine due at the pharmacy (no product code recorded). Advance care planning records only his general preferences and an unnamed agent.
  12. Focused visits. The four chronic-care follow-ups (the hepatology consultation day, day 1 of treatment, the end of treatment, and the test of cure with six-month surveillance) are documented as focused visits on the AASLD-IDSA HCV guidance and the sofosbuvir-velpatasvir label, the AASLD 2023 HCC guidance, Baveno VII and the AASLD portal hypertension and ascites guidance, the AASLD alcohol guidance, the cirrhosis pain review and CDC opioid guideline, the ADA Standards of Care, the Endocrine Society guideline and the CMID diabetes, osteoporosis and depression monographs. Two deviations are recorded instead of invented results: (1) the yearly diabetic eye examination was referred at the consultation visit but never booked because the referral was sent without an appointment request; it was booked at the end of treatment and done the next month (no retinopathy); (2) the six-month surveillance ultrasound was done about three weeks late because the recall was set from the hepatology visit and then held for the test of cure; no lesion was found, and the recall is now set from each scan date. Synthetic findings introduced: vitamin D deficiency (resolved with replacement), osteoporosis on DXA, and an A1c lower than the glucose management indicator.
  13. Consultation. The hepatology referral, written at intake when only the raised liver tests and low platelets were known, and the consultation by Mei-Ling Okonkwo, MD (a fictional consultant), on the day of the two-week visit, are S. The consultant answers the five referral questions in line with what the record shows afterwards: chronic hepatitis C with compensated cirrhosis; sofosbuvir-velpatasvir for 12 weeks with the interaction check; carvedilol without screening endoscopy; six-monthly ultrasound with alpha-fetoprotein for life, hepatitis A and B vaccination and transplant referral criteria; and pain, diabetes and alcohol care adapted to cirrhosis, with a bone density scan.

Protocol deviations

Checks the monitoring protocol called for that the schedule did not perform. Each is recorded with its outcome and corrective action, never filled with an invented result.

VisitMeasureIntervalWhat happened
2026-05-18
Progress note 04 (C-CDA)
Diabetic eye examinationYearlyA deviation: referred two visits ago but never booked, because the referral was sent without an appointment request. No harm is known; he has no visual symptoms. Corrective action: booked today for next month, with a reminder to confirm the result
2026-08-17
Progress note 05 (C-CDA)
Liver ultrasound for cancer surveillance at six monthsEvery six months in cirrhosisA deviation: due six months after the baseline scan, in July, but done a week ago, about three weeks late, because the recall was set from the hepatology visit and then held until after the test of cure. No harm resulted: no lesion (LI-RADS US-1). Corrective action: the recall is now set from the date of each scan, every six months

Orders and referrals without results in the record

VisitTypeItemStatusDetail
2026-01-26
Progress note 02 (C-CDA)
ReferralDiabetic eye examinationReferredReferred; last examination over three years ago
2026-02-23
Progress note 03 (C-CDA)
ImagingBone density (DXA)OrderedBooked in two weeks
2026-02-23
Progress note 03 (C-CDA)
ReferralDiabetic eye examinationReferredReferral made at the last visit; not yet booked
2026-09-21
Progress note 06 (C-CDA)
PreventionColorectal cancer screeningOrderedNever screened; colonoscopy ordered

Evidence to check

Retrospective claims (R)

None.

Sensitive claims

ClaimGradeStatement
CLM-0006DA news agency obituary reported that he did not quit drinking until his liver transplant in 1999.
CLM-0008DHis final years were plagued by pain from his accidents. In a newspaper interview published early in 2007 he was described as frail and reliant on an oxygen tank and an implanted drug pump to relieve his pain.

Diagnoses not confirmed

None.

Notes to read

Every note in the record, with its type. All clinical content is synthetic.

Abnormal results

DateResultValueFlag
2026-01-12Platelets118 10*3/uL (low)Low
2026-01-12Glucose (fasting)162 mg/dL (high)High
2026-01-12ALT88 U/L (high)High
2026-01-12AST96 U/L (high)High
2026-01-12Hemoglobin A1c7.4% (high)High
2026-01-12LDL cholesterol112 mg/dL (high)High
2026-01-12HDL cholesterol38 mg/dL (low)Low
2026-01-12Triglycerides178 mg/dL (high)High
2026-01-26Liver stiffness (transient elastography)26.8 kPa (high)High
2026-02-23Platelets121 10*3/uL (low)Low
2026-02-23Glucose (fasting)141 mg/dL (high)High
2026-02-23ALT81 U/L (high)High
2026-02-23AST90 U/L (high)High
2026-02-2325-hydroxyvitamin D17 ng/mL (low)Low
2026-05-18Platelets129 10*3/uL (low)Low
2026-05-18Glucose (fasting)118 mg/dL (high)High
2026-05-18Hemoglobin A1c6.4% (high)High
2026-08-17Platelets134 10*3/uL (low)Low
2026-08-17Glucose (fasting)112 mg/dL (high)High
2026-08-17Hemoglobin A1c6.3% (high)High